REGULATORY
OxyContin Gets Delayed Approval in Japan with Special Distribution Scheme Now in Place
The Ministry of Health, Labor and Welfare (MHLW) on October 29 approved Shionogi’s opioid analgesic OxyContin (oxycodone) for an additional indication of chronic pain with a seven-month delay from the typical timeline as it sees a special distribution scheme now…
To read the full story
Related Article
REGULATORY
- Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
April 9, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
April 9, 2026
- MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
- Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





